Mnemo Therapeutics
Bénédicte Balland has a diverse work experience beginning in 2003 when they were a Tutor at University Aix-Marseille II. In 2006, they became a Post-Doctoral Fellow at the University of Geneva, Switzerland, researching cellular and molecular mechanisms of addiction. Bénédicte published several papers in journals such as PLoS One (2010), Psychiatrie Science Humaine Neuroscience (PSN, 2009), Neuron (2008), Pediatr Res (2008), Dépendance (revue éditée par l’Institut Suisse de Prévention de l’Alcoolisme et autres toxicomanies, ISPA, 2007), and Science (2007). From 2010 to 2016, they worked as a Patent Engineer Biotechnology at Coralis Harle Phelip. Finally, in 2022, they began their current role as IP Director at Mnemo Therapeutics.
Bénédicte Balland obtained their Master's Degree in 2001-2002 from University Aix-Marseille II, Faculty of Sciences of Luminy, in the field of Cellular Biology and Physiology, Immunologie, Neurosciences. Bénédicte then obtained their DEA (Master2) in 2002-2003 from the same university in Neurosciences. In 2003-2006, they obtained their PhD from University Aix-Marseille II, Faculty of Medicine in Neurosciences. In 2009-2010, they obtained their CEIPI from CEIPI, University Robert Schuman Strasbourg. Bénédicte is currently enrolled in OEB since 2015.
This person is not in any teams
This person is not in any offices
Mnemo Therapeutics
1 followers
Mnemo Therapeutics is a biotechnology company focused on developing powerful cell therapies that create accessible cures for solid tumors and blood cancers. Its EnfiniT platform, a groundbreaking drug discovery engine, leverages a new class of antigens with greater tumor specificity and a suite of technologies to significantly improve T cell memory, persistence, and sensitivity. The result is dramatic improvement in the body’s immune response to overcome disease. Mnemo is built by a transatlantic team of scientists and biotech leaders united in their mission to create the most powerful immune therapies to deliver accessible cures for all patients in need.